122 Participants Needed

Q Therapeutic System for Stroke

Recruiting at 14 trial locations
IB
AL
Overseen ByAssaf Lifshitz
Stay on Your Current MedsYou can continue your current medications while participating
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new wearable device called the Q Therapeutic System (BQ 3.0), which uses gentle electromagnetic fields to aid recovery from ischemic strokes (strokes caused by blocked blood vessels in the brain). The goal is to determine if this device can reduce disability and improve recovery when used alongside regular treatments. Participants will receive either active therapy with the device or a sham (inactive) version for comparison. The trial seeks individuals who have experienced an ischemic stroke in the past 4 to 21 days and are facing certain levels of movement difficulty. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research and potentially benefit from innovative stroke recovery technology.

Do I need to stop my current medications for the trial?

The trial protocol does not specify whether you need to stop taking your current medications. However, if you are taking anti-epileptic medication, you cannot participate in the trial.

What prior data suggests that the Q Therapeutic System (BQ 3.0) is safe for use in stroke recovery?

Previous studies have shown that the Q Therapeutic System (BQ 3.0) is safe and well-tolerated. Research indicates that this device, which uses gentle electromagnetic fields to aid brain recovery after a stroke, did not cause any treatment-related side effects. Participants in these studies reported no harmful effects from using the device. This suggests that the BQ 3.0 is generally safe for people recovering from a stroke.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores a novel approach for treating ischemic stroke using electromagnetic fields. Unlike conventional treatments like clot-busting drugs or mechanical thrombectomy, which directly address blood clots, this method uses the Q Therapeutic System (BQ 3.0) to potentially enhance recovery through electromagnetic stimulation. This technique could offer a non-invasive way to improve brain function and promote rehabilitation when combined with physical and occupational therapy. If successful, this approach could provide a new avenue for stroke recovery, especially in the subacute phase, offering hope for improved outcomes.

What evidence suggests that the Q Therapeutic System (BQ 3.0) is effective for neurorecovery after a stroke?

Research has shown that the Q Therapeutic System (BQ 3.0) could aid stroke recovery. Earlier studies examined its ability to reorganize brain connections and enhance movement in stroke survivors. The results suggest that this device might reduce disability over time. In this trial, participants will be divided into two groups: one receiving active stimulation with the BQ 3.0 and the other receiving sham stimulation. Researchers will assess improvements in recovery at specific intervals, such as 45, 90, and 180 days post-stroke. The BQ 3.0 uses gentle electromagnetic fields to stimulate brain activity and support recovery.12367

Who Is on the Research Team?

JL

Jeffrey L. Saver, MD

Principal Investigator

Coordinating PI

JS

Joel Stein, MD

Principal Investigator

Coordinating PI

Are You a Good Fit for This Trial?

Inclusion Criteria

I need some help with my daily activities due to my health condition.
My arm's movement score is between 10 and 45.
I have a SAFE score greater than 0.
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-3 weeks
1 visit (in-person)

Stage 1 Treatment

Participants receive either active or sham electromagnetic field treatments, 5 times a week, for a total of 45 to 72 sessions.

9-13 weeks
Up to 5 visits per week (in-person or home-based)

Stage 2 Treatment

Participants continue with active electromagnetic field treatments, up to 5 times a week, if they completed at least 35 sessions in Stage 1.

12 weeks
Up to 5 visits per week (in-person or home-based)

Stage 3 Follow-up

Participants are monitored for long-term outcomes without receiving treatments.

12 weeks
1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Q Therapeutic System (BQ 3.0)

How Is the Trial Designed?

2

Treatment groups

Active Control

Placebo Group

Group I: BQ 3.0 Active Stimulation GroupActive Control2 Interventions
Group II: BQ 3.0 Sham Stimulation GroupPlacebo Group2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

BrainQ Technologies Ltd.

Lead Sponsor

Trials
4
Recruited
260+

Citations

NCT07095920 | RESPARK - Brain Q for Chronic Stroke

This trial tests a promising new intervention to promote post-stroke neural reorganization and functional recovery. The Q Therapeutic (BQ 3.0) is a wearable ...

Study Details | NCT06386874 | EMAGINE 2.0

Q Therapeutic System (BQ 3.0) active stimulation group: Device used: Q ... To show that the BQ therapy is effective in reducing depression, at 3 months ...

Research Examines Electromagnetic Device to Improve ...

At 45, 90, and 180 days after the stroke, researchers will assess whether the Q Therapeutic System has improved patients' outcomes and record ...

Q Therapeutic System for Chronic Stroke Recovery

Evaluate the effectiveness of the Q Therapeutic (BQ 3.0) System for individuals with chronic stroke in improving upper extremity function as ...

Q Therapeutic System for Stroke

This trial tests a promising new intervention to promote post-stroke neural reorganization and functional recovery. The Q Therapeutic (BQ 3.0) is a wearable ...

Electromagnetic Stimulation to Reduce Disability After ...

This randomized clinical trial examines whether electromagnetic network targeting field therapy accompanied by a guided physical and ...

Frequency-tuned electromagnetic field therapy improves ...

No treatment-related adverse events were reported. Conclusions: ENTF stimulation in subacute ischemic stroke patients was associated with improved UE motor ...